Stifel analyst Jonathan Block maintains Sonendo (NYSE:SONX) with a Buy and lowers the price target from $4 to $3.
Eliem Announces Updated Development Plans And The Advancement Of ETX-155 For The Treatment Of Major Depressive Disorder
Initiating a Phase 1 pharmacokinetics trial of ETX-155 to enable a Phase 2a trial in MDD planned to commence in first quarter of 2023
Sufficient capital expected to fund operations until mid-2024